Association between muscle strength and advanced fibrosis in non‐alcoholic fatty liver disease: a Korean nationwide survey
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background: We investigated the association between muscle strength and the prevalence of advanced fibrosis among individuals with non‐alcoholic fatty liver disease (NAFLD) using a nationwide cross‐sectional survey. Methods: Individuals, 20 to 79 years of age, from the Korean National Health and Nutrition Examination Surveys (KNHANES) from 2014 to 2016 were selected (N = 14 861), with sample weights applied. Muscle strength was quantified as the handgrip strength divided by the body mass index (BMI); low muscle strength (LMS) was defined as the lowest quartile (Q 1) of the handgrip strength/BMI for our sample population. NAFLD was defined as hepatic steatosis index >36. Advanced fibrosis was defined as a fibrosis‐4 index score ≥1.30 (Fibrosis FIB4). Results: The mean age of the study population was 45.6 ± 0.2 years, and 42.4% were male. As muscle strength increased, the mean BMI and age decreased accordingly, and the proportions of diabetes, dyslipidaemia, hypertension, and obesity decreased significantly (P < 0.001 for all). In a crude analysis, the LMS was associated with an increased prevalence of NAFLD (odds ratio [OR] 3.62, 95% confidence interval [CI] 3.25–4.03, P < 0.001), which remained significant even after adjustment for age, sex, obesity, insulin resistance, diabetes, hypertension, dyslipidaemia, and high‐sensitivity C‐reactive protein (OR 1.66, 95% CI 1.28–2.16, P < 0.001). In this logistic regression model, the prevalence of NAFLD decreased by 24% with each quartile increment in muscle strength (OR 0.76, 95% CI 0.68–0.85, P < 0.001). Among individuals with NAFLD (n = 2092), LMS was significantly associated with the presence of advanced fibrosis (Fibrosis FIB4) independently of age, sex, obesity, diabetes, hypertension, dyslipidaemia, and high‐sensitivity C‐reactive protein (OR 1.66, 95% CI 1.01–2.49, P = 0.015), which lost its statistical significance after additional adjustment for insulin resistance. Conclusions: Low muscle strength is independently associated with NAFLD. The significant association between LMS and advanced fibrosis in NAFLD may be mediated through insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis
McPherson, S., Hardy, T., Dufour, J.-F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., Van Gaal, L., Schattenberg, J. M., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.453 · Cited by 945
Appropriate waist circumference cutoff points for central obesity in Korean adults
Lee, S. Y., Park, H. S., Kim, D. J., Han, J. H., Kim, S. M., Cho, G. J., Kim, D. Y., Kwon, H. S., Kim, S. R., Lee, C. B., et al. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.04.013 · Cited by 904
Ferrucci, L., Penninx, B. W. J. H., Volpato, S., Harris, T. B., Bandeen‐Roche, K., Balfour, J., Leveille, S. G., Fried, L. P., & Md, J. M. G. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50605.x · Cited by 618
Srikanthan, P., Hevener, A. L., & Karlamangla, A. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010805 · Cited by 600 · cited 6×
“The association between LMS and advanced fibrosis in NAFLD subjects was found to be independent of metabolic diseases, such as DM, DL, and obesity, which seemed to be mediated through IR.”
BackgroundInfluentialHallsworth, K., Fattakhova, G., Hollingsworth, K. G., Thoma, C., Moore, S., Taylor, R., Day, C. P., & Trenell, M. I. (2011) · Gut · doi:10.1136/gut.2011.242073 · Cited by 529
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440 · cited 2×
“Recently, an independent association between appendicular skeletal muscle mass and histological severity of non-alcoholic fatty liver disease (NAFLD) has been reported.(5) Insulin resistance (IR), an important pathogenic mechanism of NAFLD,(6) also increases the risk of sarcopenia via reduction of protein synthesis an…”
BackgroundSelf-citationAssociations of Muscle Mass and Strength with All-Cause Mortality among US Older Adults
LI, R., XIA, J., ZHANG, X., GATHIRUA-MWANGI, W. G., GUO, J., LI, Y., MCKENZIE, S., & SONG, Y. (2018) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001448 · Cited by 398
Verdijk, L. B., Gleeson, B. G., Jonkers, R. A. M., Meijer, K., Savelberg, H. H. C. M., Dendale, P., & van Loon, L. J. C. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gln050 · Cited by 372
Payette, H., Roubenoff, R., Jacques, P. F., Dinarello, C. A., Wilson, P. W. F., Abad, L. W., & Harris, T. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51407.x · Cited by 245 · cited 1×
“Although IR plays a main pathogenic role in developing both NAFLD(34,35) and sarcopenia,(33) the latter may increase the severity of NAFLD through IR-independent mechanisms such as systemic inflammation.(36,37)”
BackgroundWilkes, E. A., Selby, A. L., Atherton, P. J., Patel, R., Rankin, D., Smith, K., & Rennie, M. J. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27543 · Cited by 204
New role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro
Park, M.-J., Kim, D.-I., Choi, J.-H., Heo, Y.-R., & Park, S.-H. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.04.010 · Cited by 168 · cited 1×
“and increasing myokines that are beneficial to hepatic steatosis.(49,50) Irisin has been reported to have a protective effect on hepatic steatosis,(50) and its level significantly increased after 8 weeks of initiating exercise in the resistance training group compared with that in the aerobic exercise group.”
BackgroundFujita, S., Glynn, E. L., Timmerman, K. L., Rasmussen, B. B., & Volpi, E. (2009) · Diabetologia · doi:10.1007/s00125-009-1430-8 · Cited by 164
Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver
Jelenik, T., Kaul, K., Séquaris, G., Flögel, U., Phielix, E., Kotzka, J., Knebel, B., Fahlbusch, P., Hörbelt, T., Lehr, S., et al. (2017) · Diabetes · doi:10.2337/db16-1147 · Cited by 154
KIM, H.-J., LEE, H.-J., SO, B., SON, J. S., YOON, D., & SONG, W. (2016) · Physiological Research · doi:10.33549/physiolres.932997 · Cited by 141
Oh, Y. S., Kim, H. J., Ryu, S. J., Cho, K. A., Park, Y. S., Park, H., Kim, M., Kim, C. K., & Park, S. C. (2007) · Experimental & Molecular Medicine · doi:10.1038/emm.2007.44 · Cited by 24
Effects of an acute bout of resistance exercise on fiber-type specific GLUT4 and IGF-1R expression
Gallagher, P. M., Touchberry, C. D., Teson, K., McCabe, E., Tehel, M., & Wacker, M. J. (2013) · Applied Physiology Nutrition and Metabolism · doi:10.1139/apnm-2012-0301 · Cited by 17
Cited by
Nachit, M., De Rudder, M., Thissen, J., Schakman, O., Bouzin, C., Horsmans, Y., Vande Velde, G., & Leclercq, I. A. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12646 · Cited by 82
Interaction between sarcopenia and nonalcoholic fatty liver disease
Joo, S. K., & Kim, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0358 · Cited by 78
Self-citationOsteosarcopenia in NAFLD/MAFLD: an underappreciated clinical problem in chronic liver disease
Musio, A., Perazza, F., Leoni, L., Stefanini, B., Dajti, E., Menozzi, R., Petroni, M. L., Colecchia, A., & Ravaioli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087517 · Cited by 26
“As regards the assessment of muscle strength, contrary to the CST, low HGS has been associated with NAFLD presence [37,63–66] and severity [37,63,64] and with the presence of advanced liver fibrosis [65].”
Metadata
- Authors
- Kang, S., Moon, M. K., Kim, W., & Koo, B. K.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2020-07-07
- Volume
- 11
- Issue
- 5
- Pages
- 1232-1241
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W3041378854
- Cited by
- 64
- References
- 25
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.